INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions - QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection - First-in-class next genera...
2021-02-24 14:45
6140
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, May 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (NASDAQ: INO) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to res...
2019-05-17 04:02
3543
